Navigation Links
Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings
Date:10/13/2009

entific Meeting - Washington, D.C.

Date: October, 25, 2009

Time: 1-7:30 p.m.

Interleukin Genetics will present a poster titled, "Perilipin, IL-1 and ADRB Gene Variants Identify Bariatric Surgery Patients who are Resistant to Weight Loss under Calorie Restriction in Preoperative Weight Loss Program." The poster, #322-P, highlights findings which suggest that genetic polymorphisms in perilipin, IL-1 and ADRB genes show strong association with resistance to weight loss under caloric restriction. These genetic risk markers could have important clinical utility in the medical management of obese patients and in the design of optimal weight loss programs.

In addition to the scientific presentations, Interleukin Genetics will exhibit at the following conference.

American Dietetic Association FNCE Meeting - Denver, CO

Date: October 17-20, 2009

Booth #1900

Interleukin Genetics will exhibit at the ADA's annual Food and Nutrition Conference & Expo, which will demonstrate the latest nutrition science information and foodservice trends. Highlighted at the Company's Booth will be the new Inherent Health((TM)) Weight Management Genetic Test designed to guide optimal diet and exercise regimens based on genetics.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests under the Inherent Health(TM) brand that empower consumers to prevent chronic diseases of aging, and provides genetic biomarker expertise to assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics i
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Interleukin Genetics Announces Strategic Divestment of Alan James Group
2. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
3. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
4. Interleukin Genetics Reports First Quarter 2009 Financial Results
5. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
6. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
7. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
8. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
9. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
10. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
11. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... According to the the Stevens Johnson Syndrome Foundation, Stevens ... a severe allergic reaction usually to medicine (i). The ... quickly advance causing blistering and large areas of dead skin. ... can develop at any time and seriously affect both children ... Bol, passed away after he received kidney medicine which caused ...
(Date:5/18/2013)... 2013 The product liability attorneys at Wright ... behalf of consumers nationwide who have sustained serious tendon injuries ... These cases are all part of MDL 2308 and were ... will be heard in the U.S. District Court of ... & Schulte, LLC specializes in defending the rights of those ...
(Date:5/17/2013)... 17, 2013 Daily Gossip announced on Monday ... creator of the Program Yourself Thin regime, Jim ... online website by the end of the month in order ... successfully reeducate themselves and lead a healthy lifestyle, free of ... Thin package is available for only $97 and it ...
(Date:5/17/2013)... 17, 2013 Degenerative changes to the area ... felt with compression, known as the nucleus pulposus, has been ... a new study led by researchers at the Icahn School ... the journal PLOS ONE, reinforces the importance of diabetes in ... it is the first study to demonstrate that these changes ...
(Date:5/17/2013)... York, New York (PRWEB) May 17, 2013 ... firm dedicated to protecting the rights of victims injured ... (J&J)’s DePuy Orthopaedics Inc. has said in a May ... selling some of its metal-on-metal and ceramic-on-metal hip replacement ... Articulation and the Complete Ceramic-on-Metal Acetabular Hip System will ...
Breaking Medicine News(10 mins):Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:Program Yourself Thin Review and Secrets Revealed By Daily Gossip Magazine 2Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 2Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 3Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 4Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 3
... TAMPA, Fla., Nov. 2 Romark Laboratories, ... phase II clinical trial showing that 79% of ... nitazoxanide plus,the standard of care had a sustained ... weeks following treatment, compared to 43%,of patients receiving ...
... Kensey Nash Corporation,(Nasdaq: KNSY ) today ... Optical Coherence Domain Reflectometry Guidewire, from Lawrence,Livermore National ... related to its chronic total occlusion (CTO) platform.,The ... capabilities,allowing it to sense locations, thickness, and structure ...
... Amedisys, Inc.,(Nasdaq: AMED or the "Company"), one of America,s ... Graham, President and,Chief Operating Officer, and Dale E. Redman, ... Markets 18th Annual Healthcare Conference in,New York on Tuesday, ... 9:10 a.m. Eastern time. The audio,presentation will be webcast ...
... Nov. 2 NxStage Medical, Inc.,(Nasdaq: NXTM ), ... machine, today announced its financial results for the,third quarter ... quarter of 2007 were $11.6 million, compared to,$5.5 million ... 111%. Revenues in,the chronic home dialysis market were $8.3 ...
... 2 Vista Partners announced,today that it has ... RPTP). "We believe Raptor,s operational approach will serve,as ... as it promotes,operational efficiency, reduced operating costs and ... a Phase II candidate for 2008 in,Convivia(TM), which ...
... (Nasdaq: KOSN ) will announce its third ... after market close. The announcement of Kosan,s ... a conference call and live webcast on November ... Eastern. Interested parties may access the,live call by ...
Cached Medicine News:Health News:Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C 2Health News:Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C 3Health News:Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C 4Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:Amedisys to Present at 2007 CIBC Healthcare Conference in New York 2Health News:NxStage Medical Reports Third Quarter 2007 Results 2Health News:NxStage Medical Reports Third Quarter 2007 Results 3Health News:NxStage Medical Reports Third Quarter 2007 Results 4Health News:NxStage Medical Reports Third Quarter 2007 Results 5Health News:NxStage Medical Reports Third Quarter 2007 Results 6Health News:NxStage Medical Reports Third Quarter 2007 Results 7Health News:NxStage Medical Reports Third Quarter 2007 Results 8Health News:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. 2Health News:Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results 2
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... systems, announced today that the United States Food and ... Drug application(IND) for ORMD-0801, its oral insulin capsule. ... clearance to proceed," stated Nadav Kidron ... major milestone for Oramed and we look forward to ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Technology and Research (A*STAR) and Switzerland,s ... has been dosed in a Phase 1 clinical trial with ... Qbeta virus-like particle (VLP) technology. In this first Phase 1 ... candidate and its potential to protect against H1N1 influenza infection ...
(Date:5/16/2013)... Therapeutics, (Nasdaq: NKTR ) President and Chief Executive ... to present at the upcoming 2013 UBS Global Healthcare Conference ... New York Hotel on Tuesday, May 21, 2013 at 10:00 ... via a Webcast through a link posted in the Investor ... . This Webcast will be available for replay until June ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... Inc. (NYSE: WLP ) announced today that ... the Centers for Medicare & Medicaid Services (CMS) to ... (DME MAC) for Jurisdiction B, which includes the states ... National Government Services was originally awarded ...
... Inc. (OTC Bulletin Board: AEMD ), ... address infectious disease and cancer, disclosed today that ... Hemopurifier® within U.S. Government programs that support the ... threats. The Aethlon Hemopurifier® is the first medical ...
Cached Medicine Technology:WellPoint Subsidiary Wins Durable Medical Equipment Medicare Administrative Contract Valued at $86.7 Million 2Aethlon Medical Reestablishes Biodefense Programs 2Aethlon Medical Reestablishes Biodefense Programs 3Aethlon Medical Reestablishes Biodefense Programs 4Aethlon Medical Reestablishes Biodefense Programs 5Aethlon Medical Reestablishes Biodefense Programs 6
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Inquire...
Thermometer for Round Water Bath...
... The F340 is a basic laboratory system ... pH results can be obtained when used ... 3-in-1 electrode. • Fast and easy one ... recognition for five buffers (pH 1.68, 4.00, ...
Medicine Products: